Inhibition of angiogenesis and arteriogenesis by endostatin in terminal heart failure: Differences between ischemic and dilative cardiomyopathy

MLA

HJ Geißler, et al. “Inhibition of Angiogenesis and Arteriogenesis by Endostatin in Terminal Heart Failure: Differences between Ischemic and Dilative Cardiomyopathy.” The Thoracic and Cardiovascular Surgeon, vol. 56, Jan. 2009. EBSCOhost, https://doi.org/10.1055/s-0029-1191479.

APA

HJ Geißler, C Schlensak, Heike Göbel, Wilhelm Bloch, Friedhelm Beyersdorf, P. von Samson, & Alexey Dashkevich. (2009). Inhibition of angiogenesis and arteriogenesis by endostatin in terminal heart failure: Differences between ischemic and dilative cardiomyopathy. The Thoracic and Cardiovascular Surgeon, 56. https://doi.org/10.1055/s-0029-1191479

Chicago

HJ Geißler, C Schlensak, Heike Göbel, Wilhelm Bloch, Friedhelm Beyersdorf, P. von Samson, and Alexey Dashkevich. 2009. “Inhibition of Angiogenesis and Arteriogenesis by Endostatin in Terminal Heart Failure: Differences between Ischemic and Dilative Cardiomyopathy.” The Thoracic and Cardiovascular Surgeon 56 (January). doi:10.1055/s-0029-1191479.